159550-14-8

Basic information

• Product Name: Benzoic acid, 4-[2-(2-hydroxyethoxy)ethoxy]-, methyl ester
• CAS NO: 159550-14-8
• Molecular Formula: C12H16O5
• Molecular Weight: 240.256
• Mol File: 159550-14-8.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: Benzoic acid, 4-[2-(2-hydroxyethoxy)ethoxy]-, methyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: Benzoic acid, 4-[2-(2-hydroxyethoxy)ethoxy]-, methyl ester(159550-14-8)
• EPA Substance Registry System: Benzoic acid, 4-[2-(2-hydroxyethoxy)ethoxy]-, methyl ester(159550-14-8)

Safety Data

• Hazardous Substances Data: 159550-14-8(Hazardous Substances Data)

Upstream product

• 628-89-7 2-(2-Chloroethoxy)ethanol 
• 99-76-3 methyl 4-hydroxylbenzoate 
• 99-96-7 4-hydroxy-benzoic acid 

Downstream Products

• 1194054-57-3 methyl 4-[2-(2-(tert-butyldimethylsiloxy)-ethoxy)ethoxy]benzoate 
• 1269797-63-8 4-(2-(2-fluoroethoxy)ethoxy)-N-(4-(4-(2-(2-fluoroethoxy)phenyl)piperazin-1-yl)-trans-butyl-2-enyl)benzamide 
• 1269797-15-0 methyl 4-(2-(2-fluoroethoxy)ethoxy)benzoate 
• 1269797-17-2 4-(2-(2-fluoroethoxy)ethoxy)benzoic acid 
• 1269797-27-4 4-(2-(2-fluoroethoxy)ethoxy)-N-(4-(4-(2-methoxyphenyl)piperazin-1-yl)butyl)benzamide 
• 1269797-34-3 4-(2-(2-fluoroethoxy)ethoxy)-N-(4-(4-(2-methoxyphenyl)piperazin-1-yl)-trans-butyl-2-enyl)benzamide 
• 1269797-51-4 4-(2-(2-fluoroethoxy)ethoxy)-N-(4-(4-(2-(2-fluoroethoxy)phenyl)piperazin-1-yl)butyl)benzamide 
• 1194054-65-3 2-(tert-butyl)-4-chloro-5-((4-(2-(2-hydroxyethoxyl)ethoxy)benzyl)oxy)pyridazin-3(2H)-one 

Relevant articles and documents

Photo/nickel synergistic catalysis method for monoarylation of diol

The invention discloses a photo/nickel synergistic catalysis method for monoarylation of a diol. The method directly uses a brominated aromatic hydrocarbon and a diol as raw materials, wherein the brominated aromatic hydrocarbon and the diol are simple and easy to obtain, and adopts a BODIPY organic photosensitizer and an inexpensive nickel source to synergistically catalyze cross-coupling of thediol and the brominated aromatic hydrocarbon without an additionally-added ligand to realize selective monoarylation of a diol compound, and a mono/dual arylation ratio is up to 18:1. The method disclosed by the invention has good tolerance of functional groups and is suitable for a plurality of diol compounds with different structures, such as o-diol, 1,3-diol, 1,4-diol and monodisperse polyethylene glycol; more importantly, the photosensitizer used in the method has a low using amount, the reaction temperature is close to room temperature, and the method is green, economical and highly-efficient; and the advantages make the method have higher scale synthetic value and can serve social and economic development.

Contrast agent and for the use of a synthetic composition, method and system (by machine translation)

The present invention provides compounds with imaging moieties for imaging a subject. The present invention also relates to systems, compositions, and methods for the synthesis and use of imaging agents, or precursors thereof. An imaging agent precursor may be converted to an imaging agent using the methods described herein. In some cases, a composition or plurality of imaging agents is enriched in 18 F. In some cases, an imaging agent may be used to image an area of interest in a subject, including, but not limited to, the heart, cardiovascular system, cardiac vessels, brain, and other organs.

Preparation and biodistribution of [18F]FP2OP as myocardial perfusion imaging agent for positron emission tomography

Myocardial extractions of pyridaben, a mitochondrial complex I (MC-I) inhibitor, is well correlated with blood flow. Based on the synthesis and characterization of pyridaben analogue 2-tert-butyl-5-[2-(2-[18F]fluroethoxy)ethoxy]benzyloxy]-4-chloro-2H-pyridazin-3-one ([18F]FP2OP), this study assessed its potential to be developed as myocardial perfusion imaging (MPI) agent. Methods: The tosylate labeling precursor 2-(2-(4-(tert-butyl-5-chloro-6-oxo-1,6-dihydro-pyridazin-4-yloxymethyl)benzyloxy)ethoxy)ethyl ester (OTs-P2OP) and the nonradioactive 2-tert-butyl-5-[2-(2-[19F]fluroethoxy)ethoxy]benzyloxy]-4-chloro-2H-pyridazin-3-one ([19F]FP2OP) were synthesized and characterized by IR, 1H NMR, 13C NMR and MS analysis. By substituting tosyl of precursor OTs-P2OP with 18F, the radiolabeled complex [18F]FP2OP was prepared and further evaluated for its in vitro physicochemical properties, in vivo biodistribution, the metabolic stability in mice, ex vivo autoradiography and cardiac PET/CT imaging. Results: Starting with [18F]F- Kryptofix 2.2.2./K2CO3 solution, the total reaction time for [18F]FP2OP was about 100 min, with final high-performance liquid chromatography purification included. Typical decay-corrected radiochemical yield stayed at 41 ± 5.3%, the radiochemical purity, 98% or more. Biodistribution in mice showed that the heart uptake of [18F]FP2OP was 41.90 ± 4.52%ID/g at 2 min post-injection time, when the ratio of heart/liver, heart/lung and heart/blood reached 6.83, 9.49 and 35.74, respectively. Lipophilic molecule was further produced by metabolized [18F]FP2OP in blood and urine at 30 min. Ex vivo autoradiography demonstrates that [18F]FP2OP may have high affinity with MC-I and that can be blocked by [19F]FP2OP or rotenone (a known MC-I inhibitor). Cardiac PET images were obtained in a Chinese mini-swine at 5, 15, 30 and 60 min post-injection time with high quality. Conclusion: [18F]FP2OP was synthesized with high radiochemical yield. The promising biological properties of [18F]FP2OP suggest high potential as MPI agent for positron emission tomography in the future.